Using an untargeted metabolomics approach to analyze serum metabolites in COVID-19 patients with nucleic acid turning negative
Background: The coronavirus disease of 2019 (COVID-19) is a severe public health issue that has infected millions of people. The effective prevention and control of COVID-19 has resulted in a considerable increase in the number of cured cases. However, little research has been done on a complete met...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.964037/full |
| _version_ | 1798036992640942080 |
|---|---|
| author | Wenyu Chen Ming Yao Miaomiao Chen Zhao Ou Qi Yang Yanbin He Ning Zhang Min Deng Yuqi Wu Rongchang Chen Xiaoli Tan Ziqing Kong |
| author_facet | Wenyu Chen Ming Yao Miaomiao Chen Zhao Ou Qi Yang Yanbin He Ning Zhang Min Deng Yuqi Wu Rongchang Chen Xiaoli Tan Ziqing Kong |
| author_sort | Wenyu Chen |
| collection | DOAJ |
| description | Background: The coronavirus disease of 2019 (COVID-19) is a severe public health issue that has infected millions of people. The effective prevention and control of COVID-19 has resulted in a considerable increase in the number of cured cases. However, little research has been done on a complete metabonomic examination of metabolic alterations in COVID-19 patients following treatment. The current project pursues rigorously to characterize the variation of serum metabolites between healthy controls and COVID-19 patients with nucleic acid turning negative via untargeted metabolomics.Methods: The metabolic difference between 20 COVID-19 patients (CT ≥ 35) and 20 healthy controls were investigated utilizing untargeted metabolomics analysis employing High-resolution UHPLC-MS/MS. COVID-19 patients’ fundamental clinical indicators, as well as health controls, were also collected.Results: Out of the 714 metabolites identified, 203 still significantly differed between COVID-19 patients and healthy controls, including multiple amino acids, fatty acids, and glycerophospholipids. The clinical indexes including monocytes, lymphocytes, albumin concentration, total bilirubin and direct bilirubin have also differed between our two groups of participators.Conclusion: Our results clearly showed that in COVID-19 patients with nucleic acid turning negative, their metabolism was still dysregulated in amino acid metabolism and lipid metabolism, which could be the mechanism of long-COVID and calls for specific post-treatment care to help COVID-19 patients recover. |
| first_indexed | 2024-04-11T21:20:35Z |
| format | Article |
| id | doaj.art-a17242195c4247c091ecd58affd9a7f6 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T21:20:35Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-a17242195c4247c091ecd58affd9a7f62022-12-22T04:02:38ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-08-011310.3389/fphar.2022.964037964037Using an untargeted metabolomics approach to analyze serum metabolites in COVID-19 patients with nucleic acid turning negativeWenyu Chen0Ming Yao1Miaomiao Chen2Zhao Ou3Qi Yang4Yanbin He5Ning Zhang6Min Deng7Yuqi Wu8Rongchang Chen9Xiaoli Tan10Ziqing Kong11Department of Respiration, Affiliated Hospital of Jiaxing University, Jiaxing, ChinaDepartment of Anesthesiology and Pain Research Center, Affiliated Hospital of Jiaxing University, Jiaxing, ChinaKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, ChinaKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, ChinaDepartment of Respiration, Affiliated Hospital of Jiaxing University, Jiaxing, ChinaKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, ChinaDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Infection, Affiliated Hospital of Jiaxing University, Jiaxing, ChinaCalibra Lab at DIAN Diagnostics, Hangzhou, ChinaCalibra Lab at DIAN Diagnostics, Hangzhou, ChinaDepartment of Respiration, Affiliated Hospital of Jiaxing University, Jiaxing, ChinaCalibra Lab at DIAN Diagnostics, Hangzhou, ChinaBackground: The coronavirus disease of 2019 (COVID-19) is a severe public health issue that has infected millions of people. The effective prevention and control of COVID-19 has resulted in a considerable increase in the number of cured cases. However, little research has been done on a complete metabonomic examination of metabolic alterations in COVID-19 patients following treatment. The current project pursues rigorously to characterize the variation of serum metabolites between healthy controls and COVID-19 patients with nucleic acid turning negative via untargeted metabolomics.Methods: The metabolic difference between 20 COVID-19 patients (CT ≥ 35) and 20 healthy controls were investigated utilizing untargeted metabolomics analysis employing High-resolution UHPLC-MS/MS. COVID-19 patients’ fundamental clinical indicators, as well as health controls, were also collected.Results: Out of the 714 metabolites identified, 203 still significantly differed between COVID-19 patients and healthy controls, including multiple amino acids, fatty acids, and glycerophospholipids. The clinical indexes including monocytes, lymphocytes, albumin concentration, total bilirubin and direct bilirubin have also differed between our two groups of participators.Conclusion: Our results clearly showed that in COVID-19 patients with nucleic acid turning negative, their metabolism was still dysregulated in amino acid metabolism and lipid metabolism, which could be the mechanism of long-COVID and calls for specific post-treatment care to help COVID-19 patients recover.https://www.frontiersin.org/articles/10.3389/fphar.2022.964037/fullCOVID-19SARS-CoV-2metabolomicmetabolitesmass spectrometryserum |
| spellingShingle | Wenyu Chen Ming Yao Miaomiao Chen Zhao Ou Qi Yang Yanbin He Ning Zhang Min Deng Yuqi Wu Rongchang Chen Xiaoli Tan Ziqing Kong Using an untargeted metabolomics approach to analyze serum metabolites in COVID-19 patients with nucleic acid turning negative Frontiers in Pharmacology COVID-19 SARS-CoV-2 metabolomic metabolites mass spectrometry serum |
| title | Using an untargeted metabolomics approach to analyze serum metabolites in COVID-19 patients with nucleic acid turning negative |
| title_full | Using an untargeted metabolomics approach to analyze serum metabolites in COVID-19 patients with nucleic acid turning negative |
| title_fullStr | Using an untargeted metabolomics approach to analyze serum metabolites in COVID-19 patients with nucleic acid turning negative |
| title_full_unstemmed | Using an untargeted metabolomics approach to analyze serum metabolites in COVID-19 patients with nucleic acid turning negative |
| title_short | Using an untargeted metabolomics approach to analyze serum metabolites in COVID-19 patients with nucleic acid turning negative |
| title_sort | using an untargeted metabolomics approach to analyze serum metabolites in covid 19 patients with nucleic acid turning negative |
| topic | COVID-19 SARS-CoV-2 metabolomic metabolites mass spectrometry serum |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.964037/full |
| work_keys_str_mv | AT wenyuchen usinganuntargetedmetabolomicsapproachtoanalyzeserummetabolitesincovid19patientswithnucleicacidturningnegative AT mingyao usinganuntargetedmetabolomicsapproachtoanalyzeserummetabolitesincovid19patientswithnucleicacidturningnegative AT miaomiaochen usinganuntargetedmetabolomicsapproachtoanalyzeserummetabolitesincovid19patientswithnucleicacidturningnegative AT zhaoou usinganuntargetedmetabolomicsapproachtoanalyzeserummetabolitesincovid19patientswithnucleicacidturningnegative AT qiyang usinganuntargetedmetabolomicsapproachtoanalyzeserummetabolitesincovid19patientswithnucleicacidturningnegative AT yanbinhe usinganuntargetedmetabolomicsapproachtoanalyzeserummetabolitesincovid19patientswithnucleicacidturningnegative AT ningzhang usinganuntargetedmetabolomicsapproachtoanalyzeserummetabolitesincovid19patientswithnucleicacidturningnegative AT mindeng usinganuntargetedmetabolomicsapproachtoanalyzeserummetabolitesincovid19patientswithnucleicacidturningnegative AT yuqiwu usinganuntargetedmetabolomicsapproachtoanalyzeserummetabolitesincovid19patientswithnucleicacidturningnegative AT rongchangchen usinganuntargetedmetabolomicsapproachtoanalyzeserummetabolitesincovid19patientswithnucleicacidturningnegative AT xiaolitan usinganuntargetedmetabolomicsapproachtoanalyzeserummetabolitesincovid19patientswithnucleicacidturningnegative AT ziqingkong usinganuntargetedmetabolomicsapproachtoanalyzeserummetabolitesincovid19patientswithnucleicacidturningnegative |